Mechanisms of Ultrasound Neuromodulation Effects in Diabetes

NARecruitingINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

September 30, 2023

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Insulin Sensitivity
Interventions
DEVICE

Ultrasound

The General Electric LOGIQ E10 ultrasound pulsed doppler imaging system and C1-6-D XDclear abdominal curvilinear probe will be used to administer ultrasound.

DIAGNOSTIC_TEST

OGTT with unlabeled glucose and liver NMR

Subjects will undergo an OGTT with unlabeled glucose to measure liver glycogen concentration by NMR spectroscopy.

DIAGNOSTIC_TEST

OGTT with carbon-13 labeled glucose and liver NMR

Subjects will undergo an OGTT with carbon-13 labeled glucose to measure liver glycogen synthesis rate by NMR spectroscopy.

DIAGNOSTIC_TEST

CGM glucose reading

A continuous glucose monitor (CGM) will be collecting glucose level changes over a 10-14day time period after the ultrasound.

DIAGNOSTIC_TEST

HEC - Hyperinsulinemic-Euglycemic-Clamp

A constant i.v. insulin and variable glucose infusion will be used to determine insulin sensitivity of study participants.

Trial Locations (1)

06520

RECRUITING

Yale School of Medicine, New Haven

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Yale University

OTHER